| Document |
Document Title |
|
WO/2023/094305A1 |
The present application relates to Compounds of Formula (I) and pharmaceutically acceptable salts or stereoisomers thereof, pharmaceutical compositions thereof, and their use in the treatment and prophylaxis of systemic infections, such ...
|
|
WO/2023/097187A1 |
This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some emb...
|
|
WO/2023/094303A1 |
Compounds of Formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2023/094827A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein X1, R3, R4, a, b, p, q, r, L, and Ring A are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calciu...
|
|
WO/2023/095161A1 |
The present invention relates to an improved process for the preparation of Crystalline Form-A of Cyantraniliprole of Formula-I.
|
|
WO/2023/094828A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, R1, R2, R3, R4, Y1, Y2, Y3, Y4, a, t, u, and L are as defined herein. The compounds are antagonists of the resistant (R-type) v...
|
|
WO/2023/081400A9 |
This invention is related to molecules and methods of use of said molecules or compounds comprising said molecules. A molecule may be a pomalidomide or a thalidomide analogue. A method of inducing degradation of a target protein comprisi...
|
|
WO/2023/093787A1 |
A benzodiazepine compound having a structure represented by formula (I) and serving as a ROCK II kinase inhibitor, and an application thereof in a Rho kinase inhibitor drug and a preparation method therefor.
|
|
WO/2023/096210A1 |
The present invention provides: a novel compound capable of improving the luminous efficiency, stability and lifespan of an element; an organic electrical element using same; and an electronic device therefor.
|
|
WO/2023/095860A1 |
The present invention provides a medicine useful for treating and/or preventing COVID-19. Provided is a medicine characterized by combining: (A) a compound represented by formula (I) (where: Y is N; R1 represents an optionally substitute...
|
|
WO/2023/089052A1 |
The invention relates to pharmaceutical compositions and methods of treating autophagy related diseases and disorders, and in particular neurological and/or CNS-related diseases. The present invention relates to compounds according to Fo...
|
|
WO/2023/091561A1 |
The present invention discloses compounds of Formula (la), and pharmaceutically acceptable salts thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound ...
|
|
WO/2023/088291A1 |
Disclosed in the present invention are an aromatic amine compound and an application thereof. The aromatic amine compound can effectively inhibit the tyrosine kinase activity of Abelson protein (ABL1), Abelson related protein (ABL2) and ...
|
|
WO/2023/090337A1 |
The present invention provides a method for producing a compound represented by formula (3) (in the formula (3), Q denotes a substituted or unsubstituted 5- to 6-membered or 9- to 10-membered heteroaryl group, R1 denotes a C1-6 alkyl gro...
|
|
WO/2023/090853A1 |
The present invention relates to a novel urea-based or carbamate-based P2X7 receptor antagonist compound. The novel urea-based or carbamate-based P2X7 receptor antagonist compound according to the present invention can effectively inhibi...
|
|
WO/2023/088285A1 |
A small molecule inhibitor targeting EB virus antigen protein, and/or a pharmaceutical composition comprising same, capable of being used for treating diseases caused by EB virus infection, such as, but not limited to, cancer, infectious...
|
|
WO/2023/088418A1 |
Provided are certain antiviral agents, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2023/088385A1 |
The present invention relates to a compound for degrading an EGFR protein and the use thereof. Specifically, the present invention relates to a compound as represented by formula (I), and the definitions of each group and each substituen...
|
|
WO/2023/088987A1 |
The application relates to pyridazine derivatives of the general formula (Ib), to pharmaceutical compositions comprising the compounds and to their use in the treatment of diseases and conditions such as asthma, COPD, Parkinson's and Alz...
|
|
WO/2023/088921A1 |
Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
|
|
WO/2023/088477A1 |
Disclosed in the present invention are a Bruton's tyrosine kinase degrading agent, which has a structure represented by general formula I; or a stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt and a prodrug...
|
|
WO/2023/089074A1 |
The invention relates to pharmaceutical compositions and methods of treating autophagy related diseases and disorders, in particular for a systemic treatment thereof. The present invention relates to compounds according to Formula (I) or...
|
|
WO/2023/091554A1 |
The invention provides new heteroaromatic compounds having the general formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, and n are as defined herein, compositions includ...
|
|
WO/2023/092149A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds of the present disclosure...
|
|
WO/2023/088408A1 |
A selective PARP1 inhibitor and an application thereof. Provided are a compound represented by general formula (I-A), and a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof. Also provided are a pharmaceut...
|
|
WO/2023/090942A1 |
The present invention relates to a pyrrole derivative or a pharmaceutically or sitologically acceptable salt thereof, and a composition for the prevention, amelioration or treatment of gastrointestinal disorders, comprising same as an ac...
|
|
WO/2023/091785A1 |
The present disclosure provides methods for treatment peripheral T-cell lymphoma with duvelisib.
|
|
WO/2023/090344A1 |
The present invention provides a method for producing a compound represented by formula (3) (in the formula, Q, R1, and R2 represent the same as in formula (1) and formula (2)) that includes chemically reacting a compound represented by ...
|
|
WO/2023/089375A1 |
There are provided new inhibitors of MDM2. Also provided are methods of synthesizing the agents, pharmaceutical formulations including the agents, and methods of using the agents to treat, ameliorate or cure diseases characterized by MDM...
|
|
WO/2023/092107A1 |
The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2023/092088A1 |
The present disclosure provides a compound represented by structural formula (I): (I), or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2023/088441A1 |
Disclosed are a class of KIF18A inhibitors, and specifically disclosed are a compound represented by general formula (1) and a preparation method therefor, and a use of a compound represented by general formula (1) and an isomer, crystal...
|
|
WO/2023/091461A1 |
The invention provides new heterocyclic compounds having the general formula (I), or a solvate or a pharmaceutically acceptable salt thereof: Formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as defined herein, compositions including ...
|
|
WO/2023/088620A1 |
The present invention relates to a phosphine of the formula (1), wherein - Q is SiR3R4, GeR3R4, SnR3R4, AsR3 or Se; - m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; under the proviso that m + n ≥ 1; - the groups R independently of each other re...
|
|
WO/2023/088426A1 |
The present invention relates to the field of herbicides. Disclosed are an oxobutan(-2-enoic acid) acid compound and a preparation method therefor, a herbicidal composition and the use thereof, and a herbicide. The compound has a structu...
|
|
WO/2023/088435A1 |
The present disclosure relates to a compound as represented by formula (I) and having an AHR activation effect, use thereof and a preparation method therefor. The compound has obvious AHR agonistic activity.
|
|
WO/2023/085046A1 |
The present disclosure provides an organic compound characterized by being represented by general formula [1].
|
|
WO/2023/085637A1 |
The present specification relates to a compound of chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2023/084158A1 |
The present invention relates to a compound of formula (I) wherein A, B, R1, R2, R3, R4 and R5 are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochr...
|
|
WO/2023/082397A1 |
Disclosed are an A-FABP protein inhibitor and a use thereof, relating to the technical field of metabolic diseases, and cardiovascular and cerebrovascular complications thereof. Disclosed is an A-FABP protein inhibitor, an active ingredi...
|
|
WO/2023/082020A1 |
In one aspect, there is a provided a method of treating pain in a subject in need thereof comprising administering to the subject an anaplastic lymphoma kinase (ALK) inhibitor. In one aspect, there is a provided a method of treating pain...
|
|
WO/2023/085142A1 |
Provided are novel fluorine-containing pyrimidine compounds and a method for producing the same. Compounds represented by general formula (1), (2), or (3). (In the formula, W and X each independently represent a hydrogen atom, a haloge...
|
|
WO/2023/083269A1 |
Disclosed are an aromatic heterocyclic compound and an application thereof. The present invention provides an aromatic heterocyclic compound as represented by formula I, and the compound has good LSD1 enzyme inhibitory activity, and can ...
|
|
WO/2023/084473A1 |
The present invention discloses an N-substituted bicyclic heteroaromatic compound of formula (I), (I) wherein, R, R1, R2, R4, W1, W2, A and Het are as defined in the detailed description. The present invention further discloses methods f...
|
|
WO/2023/082145A1 |
Provides compound of formula A, use in intermediates and bulk medicines thereof, and synthesis method thereof. The method avoids cumbersome separation and purification steps, reduces costs, improves reaction yield, avoids the use of POCl...
|
|
WO/2023/085432A1 |
The present invention pertains to: a compound represented by formula (I) [in the formula, R1 represents C1-C8 alkyl or the like, R2-R9 each independently represent hydrogen, a halogen, hydroxyl, NH2, Q-(C1-C8 alkyl) (Q represents O, NH, ...
|
|
WO/2023/086603A1 |
Provided herein are compounds of Formula I and pharmaceutically acceptable salts and compositions thereof. The compounds of the invention are useful for inhibiting 5-subunit- containing y-aminobutyric acid receptors (SGABAARS). Also disc...
|
|
WO/2023/083210A1 |
Disclosed is a substituted naphthyridinone derivative, which has a structure as shown in formula (I). Further provided are a pharmaceutically acceptable salt, stereoisomer and pharmaceutical composition of the derivative and the medicina...
|
|
WO/2023/086802A1 |
Processes to make intermediates to produce mesoionic pesticides are disclosed and in particular processes to produce N-(pyrimidin-5- ylmethyl)pyridin-2-amine, an important intermediate.
|
|
WO/2023/083299A1 |
A fused ring compound as an HPK1 inhibitor. Specifically, the present invention relates to a compound represented by general formula (1) and a preparation method therefor, and uses of the compound of general formula (1) and isomers, crys...
|
